NASDAQ · ELVN
Enliven Therapeutics, Inc.
$45.08+$0.30 (+0.67%)
Enliven Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
Loading market information…
NASDAQ · ORIC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ORIC Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.76% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ORIC Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.38. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ORIC Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Feb 18, 2025 |
| -$0.51+1.92% vs estimate |
| $533.00K |
| Q3 2024 | Nov 12, 2024 | -$0.49-2.08% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $22.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$45.08+$0.30 (+0.67%)
Enliven Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
$4.77+$0.18 (+3.92%)
Nuvation Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.08% below the high.
$21.48-$0.27 (-1.24%)
Tyra Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.16% below the high.
$14.15-$0.17 (-1.19%)
Syndax Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.7% below the high.
$17.83-$0.22 (-1.22%)
Janux Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.55% below the high.
$9.66-$0.18 (-1.78%)
Verastem, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.72% below the high.
$10.23-$0.29 (-2.76%)
Corvus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.04% below the high.
$15.95+$0.22 (+1.4%)
ArriVent BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.48% below the high.
